Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs announces completion of $5 billion Series C funding, aimed at advancing AI drug candidates into clinical trials; new funds will be used to develop a drug design engine and expand into more drug types, having previously raised $2.1 billion in Series B funding. The company develops drug design technology based on DeepMind's AlphaFold model and has achieved 'positive preclinical results' in the fields of oncology and immunology, collaborating with pharmaceutical companies like Eli Lilly, Novartis, and Johnson & Johnson.
Same story2 other outlets also reported this
- ITHome · AI··First
Alphabet's drug AI company Isomorphic Labs completes $500 million C round financing
- TechCrunch · AI··+1 h 11 min·Reading now
Isomorphic Labs raises $5 billion, aiming to advance AI drug candidates into clinical trials
Adds:TechCrunch mentions the company is based on DeepMind's AlphaFold model and has achieved 'positive preclinical results' in oncology and immunology.
In order of publication · later reports are added as they appear · Compared by AI from each outlet’s title and summary
In Brief
Posted:
6:50 AM PST · November 17, 2026

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.
The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.
The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.
The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.
Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.
Source: TechCrunch · AI · techcrunch.com